Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 13;226(5):896-900.
doi: 10.1093/infdis/jiac011.

Incidence of Malignancies Among Patients With Chronic Hepatitis B in US Health Care Organizations, 2006-2018

Philip R Spradling  1 , Jian Xing  1 , Yuna Zhong  1 , Loralee B Rupp  2 , Anne C Moorman  1 , Mei Lu  2 , Eyasu H Teshale  1 , Mark A Schmidt  3 , Yihe G Daida  4 , Joseph A Boscarino  5 , Stuart C Gordon  2   6
Affiliations

Incidence of Malignancies Among Patients With Chronic Hepatitis B in US Health Care Organizations, 2006-2018

Philip R Spradling et al. J Infect Dis. .

Abstract

Hepatitis B virus (HBV) infection causes hepatocellular carcinoma but its association with other cancers is not well established. We compared age-adjusted incidence of primary cancers among 5773 HBV-infected persons with US cancer registries during 2006-2018. Compared with the US population, substantially higher incidence among HBV-infected persons was observed for hepatocellular carcinoma (standardized rate ratio [SRR], 30.79), gastric (SRR, 7.95), neuroendocrine (SRR, 5.88), cholangiocarcinoma (SRR, 4.62), and ovarian (SRR, 3.72) cancers, and non-Hodgkin lymphoma (SRR, 2.52). Clinicians should be aware of a heightened potential for certain nonhepatic malignancies among hepatitis B patients, as earlier diagnosis favors improved survival.

Keywords: cancer; hepatitis B; incidence.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. S. C. G. receives grant/research support from AbbVie Pharmaceuticals, CymaBay, Gilead Sciences, Intercept Pharmaceuticals, and Merck. M. L., J. A. B., M. A. S., Y. G. D., J. L., and L. B. R. receive research grant support from Gilead Sciences and Intercept Pharmaceuticals. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Publication types

MeSH terms

Grants and funding